Cipla shares jumped on Tuesday after the company announced the launch of Serroflo, its Salmeterol/ Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market.

Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.

Shares of the company are trading at Rs 568.65, up Rs 38.95, or 7.35% at the Bombay Stock Exchange (BSE) on Tuesday at 9:47 a.m.

The scrip has touched an intra-day high of Rs 575.20 and low of Rs 532.10. The total volume of shares traded at the BSE is 364,933.